The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Peptide and Lyme Disease: Tissue Repair and Immune Support Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law FDA's Overreach on Compounded Peptides